Enoxaparin for neonatal thrombosis: A call for a higher dose for neonates

Thrombosis Research

Volumn 122, Issue 6, 2008, Pages 826-830

  Malowany, Janet I ^a,b   Monagle, Paul ^b   Knoppert, David C ^a,b   Lee, David S C ^a,b   Wu, John ^b,c   McCusker, Patricia ^b,d   Massicotte, M Patricia ^b,e   Williams, Suzan ^b,f   Chan, Anthony K C ^b,g   for Canadian Paediatric Thrombosis and Hemostasis Network, ^b  

^a WESTERN UNIVERSITY   (Canada)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BC CHILDREN S HOSPITAL   (Canada)

^d CANCERCARE MANITOBA   (Canada)

^e STOLLERY CHILDREN S HOSPITAL   (Canada)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN;

BLEEDING; BRAIN HEMORRHAGE; CATHETER; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; HUMAN; INJECTION SITE CONTUSION; PERICARDIAL EFFUSION; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

ANTICOAGULANTS; CATHETERS, INDWELLING; ENOXAPARIN; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; THROMBOSIS;

EID: 52049089218     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.11.009     Document Type: Review

References (34)

1. Chalmers E.A. Epidemiology of venous thromboembolism in neonates and children. Thromb Res 118 (2006) 3-12
2. Thornburg C., and Pipe S. Neonatal thromboembolic emergencies. Semin Fetal Neonatal Med 11 (2006) 198-206
3. Fareed J., Hoppensteadt D., Walenga J., Iqbal O., Ma Q., Jeske W., et al. Pharmacodynamic and pharmacokinetic properties of enoxaparin: implications for clinical practice. Clin Pharmacokinet 42 (2003) 1043-1057
4. Hirsh J., Warkentin T.E., Shaughnessy S.G., Anand S.S., Halperin J.L., Raschke R., et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 (2001) 64S-94S
5. Monagle P., Chan A., Massicotte P., Chalmers E., and Michelson A.D. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 645S-687S
6. Bartelink I.H., Rademaker C.M., Schobben A.F., and van den Anker J.N. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 45 (2006) 1077-1097
7. Reiter P.D. Neonatal pharmacology and pharmacokinetics. Neoreviews 3 (2002) e229-e236
8. Malowany J.I., Knoppert D.C., Chan A.K., Pepelassis D., and Lee D.S. Enoxaparin use in the neonatal intensive care unit: experience over 8 years. Pharmacotherapy 27 (2007) 1263-1271
9. Michaels L.A., Gurian M., Hegyi T., and Drachtman R.A. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant. Pediatrics 114 (2004) 703-707
10. Massicotte P., Adams M., Marzinotto V., Brooker L.A., and Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 128 (1996) 313-318
11. Schmidt B., and Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 96 (1995) 939-943
12. Ho S.H., Wu J.K., Hamilton D.P., Dix D.B., and Wadsworth L.D. An assessment of published pediatric dosage guidelines for enoxaparin: a retrospective review. J Pediatr Hematol Oncol 26 (2004) 561-566
13. Merkel N., Gunther G., and Schobess R. Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients. Acta Haematol 115 (2006) 230-236
14. McCusker P.J., Seifert B.W., and Israels S.J. Higher doses of enoxaparin are required to achieve therapeutic heparin (aXa) levels in neonates (NBs) with venous thromboembolic disease (VTE). [abstract]. Blood 102 (2003) 1155
15. Obaid L., Byrne P.J., and Cheung P.Y. Compartment syndrome in an ELBW infant receiving low-molecular-weight heparins. J Pediatr 144 (2004) 549
16. Punter F.A., McCusker P.J., Seshia M.M.K., Israels S.J., and Seifert B.W. Retrospective analysis of the minimum dosage requirements for enoxaparin in neonates with thromboembolic disease. [abstract]. ASH annual meeting abstracts vol. 104 (2004) 1770
17. Streif W., Goebel G., Chan A.K., and Massicotte M.P. Use of low molecular mass heparin (enoxaparin) in newborn infants: a prospective cohort study of 62 patients. Arch Dis Child Fetal Neonatal Ed 88 (2003) F365-370
18. Manco-Johnson M.J. How I treat venous thrombosis in children. Blood 107 (2006) 21-29
19. Stephens D., Ginde S., Torres A., Wohrley J., Deshpande G., and Tarantino M. Monitoring enoxaparin (E) treatment in children: is it useful?. [abstract]. PAS2005 vol. 57 (2005) 375
20. Bontadelli J., Moeller A., Schmugge M., Schraner T., Kretschmar O., Bauersfeld U., et al. Enoxaparin therapy for arterial thrombosis in infants with congenital heart disease. Intensive Care Med 33 (2007) 1978-1984
21. Belletrutti M., Bauman M., Mitchell L., and Massicotte M.P. Does increasing the starting dose of enoxaparin result in better treatment of children requiring thromboprophylaxis?. A retrospective cohort study E-PAS2007 vol. 61 (2007) 6316.11 [abstract]
22. Volz S., Schinzel H., Keune N., Neukirch M., Schmidtke S., and Stopfkuchen H. Low molecular heparin for treatment of venous thrombosis in two very low-birth-weight pre-term infants with genetic risk factors. Klin Padiatr 218 (2006) 226-229
23. Malowany J.I., Knoppert D.C., Chan A.K.C., and Lee D.S. Suboptimal dosing of enoxaparin in preterm infants. [abstract]. E-PAS2007 vol. 61 (2007) 6315.4
24. Manco-Johnson M., Graham D., Valentino L., and Knapp-Clevenger R. Low molecular weight heparin dose requirements are age-related through childhood. [abstract]. PAS2003 vol. 53 (2003) 1622
25. Manco-Johnson M., Graham D., Valentino L., and Knapp-Clevenger R. Low-molecular-weight heparin dose requirements are age-related through childhood. [abstract]. J Thromb Haemost 1 (2003) P1879
26. Levy D., Dix D., Marzinotto V., Charpentier K., and Massicotte M.P. Low molecular weight heparin therapy in infants: a prospective cohort study. [abstract]. PAS2000 vol. 47 (2000) 2428
27. Dix D., Andrew M., Marzinotto V., Charpentier K., Bridge S., Monagle P., et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 136 (2000) 439-445
28. Hanas R. Reducing injection pain in children and adolescents with diabetes: a review of indwelling catheters. Pediatr Diabetes 5 (2004) 102-111
29. de Jong M.E., Carbiere T., and van den Heuvel-Eibrink M.M. The use of an insuflon device for the administration of G-CSF in pediatric cancer patients. Support Care Cancer 14 (2006) 98-100
30. Rouss K., Gerber A., Albisetti M., Hug M., and Bernet V. Long-term subcutaneous morphine administration after surgery in newborns. J Perinat Med 35 (2007) 79-81
31. Dyer S.L., Collins C.T., Baghurst P., Saxon B., and Meachan B. Insuflon versus subcutaneous injection for cytokine administration in children and adolescents: a randomized crossover study. J Pediatr Oncol Nurs 21 (2004) 79-86
32. Andrew M., Paes B., Milner R., Johnston M., Mitchell L., Tollefsen D.M., et al. Development of the human coagulation system in the healthy premature infant. Blood 72 (1988) 1651-1657
33. Kuhle S., and Massicotte M.P. Maturation of the coagulation system during childhood. Prog Pediatr Cardiol 21 (2005) 3-7
34. Kuhle S., Male C., and Mitchell L. Developmental hemostasis: pro- and anticoagulant systems during childhood. Semin Thromb Hemost 29 (2003) 329-338